NY-ESO-1 peptide 157–165 presented by HLA-A*02:01 (NY-ESO-1_157–165/HLA-A*02:01)

The NY-ESO-1 peptide 157–165 presented by HLA-A*02:01 is a peptide–MHC class I complex formed from the cancer-testis antigen NY-ESO-1, mainly expressed in germ cells but aberrantly expressed in various tumors. Its SLLMWITQC peptide sequence is displayed via HLA-A*02:01 molecules on cancer cells, triggering a strong immune response due to its high immunogenicity. Immunotherapies—such as T cell receptor–engineered T cells and peptide vaccines—target this complex to selectively attack tumor cells in patients expressing HLA-A*02:01 and NY-ESO-1. Clinical trials show promising efficacy in several cancers, with limited safety concerns due to the antigen’s tumor-restricted expression; however, immune escape through antigen loss or MHC downregulation can limit long-term responses[4][5][6][1][2][3][8].

Other names

NY-ESO-1 (157–165) peptide–HLA-A*02 complexSLLMWITQC–HLA-A*02:01 complexNY-ESO-1 SLLMWITQC/HLA-A2HLA-A2/NY-ESO-1 157–165New York esophageal squamous cell carcinoma 1 peptide–HLA-A2

TCR-engineered T cells: recognize and kill tumor cells presenting NY-ESO-1 157–165 via HLA-A*02:01[2][4][3][6] Peptide vaccines: stimulate NY-ESO-1–specific T cell immunity, both CD8+ (cytotoxic) and CD4+ (helper) T cells[5][6]